Skip to main content
SpringerLink
Log in

Esketamine nasal spray too costly for treatment-resistant depression

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ross EL, et al. Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatric Services : 7 Jul 2020. Available from: URL: https://doi.org/10.1176/appi.ps.201900625

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esketamine nasal spray too costly for treatment-resistant depression. PharmacoEcon Outcomes News 857, 13 (2020). https://doi.org/10.1007/s40274-020-6950-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6950-y

Search

Navigation